0001104659-23-001925.txt : 20230106 0001104659-23-001925.hdr.sgml : 20230106 20230106175720 ACCESSION NUMBER: 0001104659-23-001925 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230105 FILED AS OF DATE: 20230106 DATE AS OF CHANGE: 20230106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fortress Biotech, Inc. CENTRAL INDEX KEY: 0001429260 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38128 FILM NUMBER: 23516121 BUSINESS ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 1111 KANE CONCOURSE STREET 2: SUITE 301 CITY: BAY HARBOR ISLANDS STATE: FL ZIP: 33154 FORMER NAME: FORMER CONFORMED NAME: CORONADO BIOSCIENCES INC DATE OF NAME CHANGE: 20080310 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc. CENTRAL INDEX KEY: 0001651407 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472568632 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 781-652-4500 MAIL ADDRESS: STREET 1: 95 SAWYER ROAD STREET 2: SUITE 110 CITY: WALTHAM STATE: MA ZIP: 02453 4 1 tm232299-1_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2023-01-05 0 0001651407 Checkpoint Therapeutics, Inc. CKPT 0001429260 Fortress Biotech, Inc. 1111 KANE CONCOURSE SUITE 301 BAY HARBOR ISLANDS FL 33154 0 0 1 0 COMMON STOCK, PAR VALUE $0.0001 2023-01-05 4 A 0 368907 0.00 A 1503713 D Class A Common Stock, par value $0.0001 Common Stock 700000 700000 D The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual equity fee grant. Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split. The total number of shares beneficially owned by the Reporting Person includes those transactions as disclosed on the table filed herewith as Exhibit 99. Each share of the Issuer's Class A Preferred Stock is convertible at any time at the option of the Reporting Person into one share of the Issuer's Common Stock and has no expiration date. /s/ Samuel Berry, General Counsel and Authorized Agent 2023-01-06 EX-99 2 tm232299d1_ex99.htm EXHIBIT 99

Exhibit 99

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)⁽³⁾			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) ⁽³⁾	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
COMMON STOCK, PAR VALUE $0.0001	1/1/2018		A		59,183⁽¹⁾	A	$0.00	329,454	D
COMMON STOCK, PAR VALUE $0.0001	3/12/2018		A		13,225⁽²⁾	A	$0.00	342,679	D
COMMON STOCK, PAR VALUE $0.0001	9/26/2018		A		4,604⁽²⁾	A	$0.00	347,283	D
COMMON STOCK, PAR VALUE $0.0001	1/1/2019		A		96,043⁽¹⁾	A	$0.00	443,326	D
COMMON STOCK, PAR VALUE $0.0001	2/14/2019		A		225⁽²⁾	A	$0.00	443,551	D
COMMON STOCK, PAR VALUE $0.0001	6/28/2019		A		2,494⁽²⁾	A	$0.00	446,045	D
COMMON STOCK, PAR VALUE $0.0001	9/24/2019		A		2,834⁽²⁾	A	$0.00	448,879	D
COMMON STOCK, PAR VALUE $0.0001	9/30/2019		A		22⁽²⁾	A	$0.00	448,901	D
COMMON STOCK, PAR VALUE $0.0001	11/27/2019		A		38,500⁽²⁾	A	$0.00	487,401	D
COMMON STOCK, PAR VALUE $0.0001	11/27/2019		A		106⁽²⁾	A	$0.00	487,507	D
COMMON STOCK, PAR VALUE $0.0001	2/6/2020		J		2,500⁽⁴⁾	D	$0.00	485,007	D
COMMON STOCK, PAR VALUE $0.0001	6/4/2020		A		145,931⁽¹⁾	A	$0.00	630,938	D
COMMON STOCK, PAR VALUE $0.0001	6/30/2020		A		3,257⁽²⁾	A	$0.00	634,195	D
COMMON STOCK, PAR VALUE $0.0001	9/22/2020		A		5,777⁽²⁾	A	$0.00	639,972	D
COMMON STOCK, PAR VALUE $0.0001	9/22/2020		A		18,304⁽²⁾	A	$0.00	658,276	D
COMMON STOCK, PAR VALUE $0.0001	12/30/2020		A		3,724⁽²⁾	A	$0.00	662,000	D
COMMON STOCK, PAR VALUE $0.0001	1/1/2021		A		174,245⁽¹⁾	A	$0.00	836,245	D

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)⁽³⁾			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) ⁽³⁾	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
COMMON STOCK, PAR VALUE $0.0001	3/29/2021		A		17,563⁽¹⁾	A	$0.00	853,808	D
COMMON STOCK, PAR VALUE $0.0001	6/29/2021		A		8,436⁽²⁾	A	$0.00	862,244	D
COMMON STOCK, PAR VALUE $0.0001	9/29/2021		A		1,153⁽²⁾	A	$0.00	863,397	D
COMMON STOCK, PAR VALUE $0.0001	11/30/2021		A		2,597⁽²⁾	A	$0.00	865,994	D
COMMON STOCK, PAR VALUE $0.0001	1/1/2022		A		212,142⁽¹⁾	A	$0.00	1,078,136	D
COMMON STOCK, PAR VALUE $0.0001	3/31/2022		A		9,355⁽²⁾	A	$0.00	1,087,491	D
COMMON STOCK, PAR VALUE $0.0001	4/5/2022		A		220⁽²⁾	A	$0.00	1,087,711	D
COMMON STOCK, PAR VALUE $0.0001	6/29/2022		A		1,189⁽²⁾	A	$0.00	1,088,990	D
COMMON STOCK, PAR VALUE $0.0001	9/27/2022		A		2,129⁽²⁾	A	$0.00	1,091,029	D
COMMON STOCK, PAR VALUE $0.0001	12/6/2022		A		424⁽²⁾	A	$0.00	1,091,453	D
COMMON STOCK, PAR VALUE $0.0001	12/16/2022		A		43,353⁽²⁾	A	$0.00	1,134,806	D

Explanation of Responses:

1. The Reporting Person is entitled to an annual equity fee grant from the Issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the annual equity fee grant.

2. The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing.

3. Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the “Reverse Stock Split”). The amount of common stock reflected in this Exhibit 99 has been adjusted to reflect the Reverse Stock Split.

4. Transfer to employees as service grants in consideration of services provided to the Reporting Person and to Issuer.